Pseudomonas cepacia in cystic fibrosis
O VER THE PAST DECADE. PSEUDOMONAS CEPACIA I LAS BEcome a cause of great concern in patients with cystic fibrosis. Among the many questions about infection with P cepacia are:
• Is P cepacia the direct cause of !.he 'fulminant cepacia syndrome· (1) caused such con cern a mong patients with cystic fibrosis and !.heir fa milies. Based on their review of what is known and not known a bout the epidem iology of P cepacia, the committee has made recommendations on how best to prevent pe rson-to-person spread of P cepacia. Their recommendations seem eminently sensible and sufficient to minimize whateve r the risk of such transmission may be without creating unnecessary ha rdship to caniers .
The s ignificance of the statem ent rests not only on the r ecommendations on infection control re lative to P cepacia. Equally important is the clear delineation of the research questions which must be a nswered in order to d etermine how P cepacia is acquired. what factors determine its inciden ce and prevalence. and how P cepacia causes lung damage in patients with cystic fibros is. The s tate ment con cludes with a call to ali those involved in !.he care of patients with cystic fibrosis to colla bora te voluntarily in the first step of a Canada-wide s tudy of P cepacia in establishing a central repository of P cepacia strains. If cystic fibrosi centres across Canad a do h eed this request. the creation of s u ch a collection will be invaluable in learning more about the epid emiology of P cepacia.
A second article in this issue (page 166) describes a second. essential precondition of any nationwide study of P cepacia: !.he introduction , into all m icrobiology laboratories associated with cystic fibrosis centres. of optimal m ethods for microbiological processing of rep iratory specimens from patients with cystic fibrosis. One of !.he problems wh ich has delayed acqu i ilion of knowledge of !.he epidemiology of P cepacia has been the lack of standardization o f microbiological methods and the delayed recognition of the specialized methods required to detect Pcepacia in sputum from patients with cystic fibrosis. Recognition of the need for such standa rdization o f m e thods by a ll microbiology laboratories involved wilh cystic fibros i c linics is the first and essential step. As pointed out in U1e article. it will a ! o be n ecessary to establis h accredita tion procedures and profic ie n cy tes ting programs so that the laboratories will be a ble to provide quality control of !.he ir ability to identify P cepacia and other pathogens in respiratory secretions of cystic fibrosi patients.
